标题
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-12-19
DOI
10.3389/fimmu.2022.1061394
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II study of SHR-1701 combined with famitinib in the treatment of advanced pancreatic cancer or biliary tract cancer.
- (2022) Jing Xie et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- (2022) Ming Yi et al. Molecular Cancer
- Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
- (2022) Bo Cheng et al. Cancer Communications
- Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
- (2022) Kim R.M. Blenman et al. CLINICAL CANCER RESEARCH
- Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
- (2022) Keigo Chida et al. CLINICAL CANCER RESEARCH
- Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
- (2022) Mengke Niu et al. Frontiers in Immunology
- SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of Phase I Study
- (2022) Jifeng Feng et al. CLINICAL CANCER RESEARCH
- A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.
- (2022) Jun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
- (2022) Tomoko Yamazaki et al. LANCET ONCOLOGY
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- GARP as a Therapeutic Target for the Modulation of Regulatory T Cells in Cancer and Autoimmunity
- (2022) Niklas Zimmer et al. Frontiers in Immunology
- Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
- (2022) Yan Lan et al. Journal for ImmunoTherapy of Cancer
- TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
- (2022) Xueke Shi et al. Journal of Hematology & Oncology
- Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
- (2022) Ming Yi et al. Journal of Hematology & Oncology
- LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity
- (2022) Akshay T. Krishnamurty et al. NATURE
- Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor
- (2022) Jiyoung Park et al. Scientific Reports
- Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
- (2021) Ming Yi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
- (2021) Zi Yin et al. Journal for ImmunoTherapy of Cancer
- The use of luspatercept for thalassemia in adults
- (2021) Maria Domenica Cappellini et al. Blood Advances
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy
- (2021) Lei Li et al. Science Advances
- Novel therapies emerging in oncology to target the TGF-β pathway
- (2021) Byung-Gyu Kim et al. Journal of Hematology & Oncology
- Immunotherapies targeting stimulatory pathways and beyond
- (2021) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Sustained Delivery of SB-431542, a Type I Transforming Growth Factor Beta-1 Receptor Inhibitor, to Prevent Arthrofibrosis
- (2021) Andy J. Lee et al. TISSUE ENGINEERING PART A
- Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
- (2021) James J. Harding et al. Cancer Medicine
- Latent TGF-β Activation Is a Hallmark of the Tenascin Family
- (2021) Alexandre Aubert et al. Frontiers in Immunology
- Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
- (2021) Yoong Wearn Lim et al. BMC BIOLOGY
- Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.
- (2021) Dan Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.
- (2021) Meiqi Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling
- (2021) Xuecong Wang et al. Cancers
- The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance
- (2021) Bikash Chandra Jena et al. CANCER LETTERS
- Combination strategies to maximize the benefits of cancer immunotherapy
- (2021) Shaoming Zhu et al. Journal of Hematology & Oncology
- Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
- (2021) James L. Gulley et al. Molecular Oncology
- High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
- (2021) Ying Ni et al. npj Precision Oncology
- Luspatercept: First Approval
- (2020) Anthony Markham DRUGS
- Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models
- (2020) Eunji Hong et al. Scientific Reports
- TGF-beta: a master immune regulator
- (2020) Christopher Larson et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
- (2020) M. Domenica Cappellini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
- (2020) Constance J. Martin et al. Science Translational Medicine
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- Targeting immune checkpoints in hematological malignancies
- (2020) Basit Salik et al. Journal of Hematology & Oncology
- Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
- (2020) Grégoire de Streel et al. Nature Communications
- Extracellular Vesicles as Biomarkers in Cancer Immunotherapy
- (2020) Matthen Mathew et al. Cancers
- Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
- (2020) Rodney P Rocconi et al. LANCET ONCOLOGY
- TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
- (2020) Angelo L. Grauel et al. Nature Communications
- Recent progress in TGF-β inhibitors for cancer therapy
- (2020) Cheng-Yi Huang et al. BIOMEDICINE & PHARMACOTHERAPY
- Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
- (2019) Bixia Tang et al. Journal of Hematology & Oncology
- Specificity, versatility, and control of TGF-β family signaling
- (2019) Rik Derynck et al. Science Signaling
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Molecular Engineering of the TGF-β Signaling Pathway
- (2019) Zhike Zi JOURNAL OF MOLECULAR BIOLOGY
- EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
- (2019) K Hastings et al. ANNALS OF ONCOLOGY
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
- (2019) Claire S Reader et al. JOURNAL OF PATHOLOGY
- The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector
- (2019) Wenjuan Dong et al. Cancer Discovery
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
- (2019) Huynh et al. Biomolecules
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- TGF-β signaling in cell fate control and cancer
- (2019) Yi Yu et al. CURRENT OPINION IN CELL BIOLOGY
- Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
- (2019) Jeffrey C. Thompson et al. LUNG CANCER
- Impaired Tumor-infiltrating T Cells in Patients with COPD Impacts Lung Cancer Response to PD-1 Blockade
- (2018) Jérôme Biton et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- The role of TGF-β/SMAD4 signaling in cancer
- (2018) Ming Zhao et al. International Journal of Biological Sciences
- Gut microbiome modulates efficacy of immune checkpoint inhibitors
- (2018) Ming Yi et al. Journal of Hematology & Oncology
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Prognostic Significance of PD-L1 + and CD8 + Immune Cells in HPV + Oropharyngeal Squamous Cell Carcinoma
- (2018) Benjamin Solomon et al. Cancer Immunology Research
- Abstract 1759: AVID200, a highly potent TGF-beta trap, exhibits optimal isoform selectivity for enhancing anti-tumor T-cell activity, without promoting metastasis or cardiotoxicity
- (2018) Maureen D. O'Connor-McCourt et al. CANCER RESEARCH
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Intracellular and extracellular TGF-β signaling in cancer: some recent topics
- (2018) Kohei Miyazono et al. Frontiers of Medicine
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- TGF-β Family Signaling in Tumor Suppression and Cancer Progression
- (2017) Joan Seoane et al. Cold Spring Harbor Perspectives in Biology
- Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
- (2017) Masaki Terabe et al. OncoImmunology
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- TGF-β: the master regulator of fibrosis
- (2016) Xiao-ming Meng et al. Nature Reviews Nephrology
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induced Regulatory T Cells: Their Development, Stability, and Applications
- (2016) Mitsuhiro Kanamori et al. TRENDS IN IMMUNOLOGY
- TGF-β Signaling from Receptors to Smads
- (2016) Akiko Hata et al. Cold Spring Harbor Perspectives in Biology
- Non-Smad Signaling Pathways of the TGF-β Family
- (2016) Ying E. Zhang Cold Spring Harbor Perspectives in Biology
- TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
- (2016) B. V. Park et al. Cancer Discovery
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Belagenpumatucel-L for the treatment of non-small cell lung cancer
- (2015) Erika Rijavec et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- (2015) Michael Lahn et al. Drug Design Development and Therapy
- First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
- (2014) Jordi Rodon et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Integrin αvβ6 in Breast Cancer
- (2014) Kate M. Moore et al. JNCI-Journal of the National Cancer Institute
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- TGF-β Activation and Function in Immunity
- (2013) Mark A. Travis et al. Annual Review of Immunology
- A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors
- (2013) Yutaka Fujiwara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer
- (2012) N. I. Fleming et al. CANCER RESEARCH
- LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF- and BMP-Associated Proinflammatory and Proangiogenic Signals
- (2012) P. Flechsig et al. CLINICAL CANCER RESEARCH
- Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study
- (2012) Giorgio V. Scagliotti et al. Journal of Thoracic Oncology
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis and modulates key biomarkers in vivo
- (2012) C Eberlein et al. ONCOGENE
- A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma
- (2011) John M. Kirkwood et al. CANCER
- TGF-beta signalling in colon carcinogenesis
- (2011) Pavlos Lampropoulos et al. CANCER LETTERS
- Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
- (2011) T. Meier et al. MOLECULAR CANCER THERAPEUTICS
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
- (2009) J Nemunaitis et al. CANCER GENE THERAPY
- Effect of IN-1130, a Small Molecule Inhibitor of Transforming Growth Factor-β Type I Receptor/Activin Receptor-Like Kinase-5, on Prostate Cancer Cells
- (2008) Geun Taek Lee et al. JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started